Diagnosis and Management of Pediatric Venous Thromboembolism New Therapies on the Horizon

被引:0
作者
Doshi, Bhavya S. [1 ,2 ]
Ellison, Angela M. [1 ,3 ]
机构
[1] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA
[3] Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA
关键词
venous thromboembolism; anticoagulation; UNFRACTIONATED HEPARIN; ORAL RIVAROXABAN; D-DIMER; CHILDREN; DABIGATRAN; THROMBOSIS; WARFARIN; RISK; ADOLESCENTS; RESISTANCE;
D O I
10.1097/PEC.0000000000002431
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The incidence of venous thromboembolism (VTE) is increasing in pediatric patients. Prompt recognition and evaluation of VTE in young patients could prevent significant morbidity or mortality. In contrast to VTE in adults, current treatment guidelines are largely based on expert opinion as limited randomized controlled trial data exist about the appropriate management in pediatric patients with traditional anticoagulants. However, recently approved direct-acting oral anticoagulants in adults are also being investigated in pediatric VTE and these data could inform future evidence-based treatment principles. Thus, healthcare providers must be well informed about the management of pediatric VTE and the data from these trials to date. This continuing medical education article will provide a summary of management of pediatric VTE with particular emphasis on emerging direct-acting oral anticoagulants.
引用
收藏
页码:273 / 279
页数:7
相关论文
共 66 条
[21]  
Fiamoli Veronika, 2011, Thrombosis, V2011, P981497, DOI 10.1155/2011/981497
[22]  
Food and Drug Administration, 2010, CLIN PHARM BIOPHARMA
[23]  
Food and Drug Administration, 2012, CLIN PHARMACOLOGYBIO
[24]   Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents [J].
Fukuda, Toshio ;
Honda, Yuko ;
Kamisato, Chikako ;
Morishima, Yoshiyuki ;
Shibano, Toshiro .
THROMBOSIS AND HAEMOSTASIS, 2012, 107 (02) :253-259
[25]   Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation [J].
Furie, B ;
Furie, BC .
TRENDS IN MOLECULAR MEDICINE, 2004, 10 (04) :171-178
[26]   Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children [J].
Greene, L. A. ;
Law, C. ;
Jung, M. ;
Walton, S. ;
Ignjatovic, V. ;
Monagle, P. ;
Raffini, L. J. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (09) :1554-1557
[27]   Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability [J].
Halton, J. M. L. ;
Albisetti, M. ;
Biss, B. ;
Bomgaars, L. ;
Brueckmann, M. ;
Gropper, S. ;
Harper, R. ;
Huang, F. ;
Luciani, M. ;
Maas, H. ;
Tartakovsky, I. ;
Mitchell, L. G. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (11) :2147-2157
[28]   Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism [J].
Halton, Jacqueline M. L. ;
Picard, Anne-Caroline ;
Harper, Ruth ;
Huang, Fenglei ;
Brueckmann, Martina ;
Gropper, Savion ;
Maas, Hugo ;
Tartakovsky, Igor ;
Nurmeev, Ildar ;
Mitchell, Lesley G. ;
Brandao, Leonardo R. ;
Chalmers, Elizabeth ;
Albisettil, Manuela .
THROMBOSIS AND HAEMOSTASIS, 2017, 117 (11) :2168-2175
[29]   Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents An open-label phase IIa study [J].
Halton, Jacqueline M. L. ;
Lehr, Thorsten ;
Cronin, Lisa ;
Lobmeyer, Maximilian T. ;
Haertter, Sebastian ;
Belletrutti, Mark ;
Mitchell, Lesley G. .
THROMBOSIS AND HAEMOSTASIS, 2016, 116 (03) :461-471
[30]   Monitoring unfractionated heparin in children: a parallel-cohort randomized controlled trial comparing 2 dose protocols [J].
Hanslik, Andreas ;
Kitzmueller, Erwin ;
Tran, Ulrich S. ;
Thom, Katharina ;
Karapetian, Hratsch ;
Prutsch, Nicole ;
Voitl, Jasmin ;
Michel-Behnke, Ina ;
Newall, Fiona ;
Male, Christoph .
BLOOD, 2015, 126 (18) :2091-2097